Kimmo Porkka

23PUBLICATIONS
264CO-AUTHORS
Haematological tumoursMedical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological modellingEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Oct 09, 2026
RUNX1 aberrations in blast-phase chronic myeloid leukaemia induce the RNA-binding protein SPATS2L, which promotes growth, survival and stress granule assembly.

|Oct 06, 2026
Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

|Aug 14, 2026
TIM3 Blockade with Hypomethylating Therapy Restores NK Cell and Cytotoxic CD4+ T-cell Activity in Patients with AML or MDS.

|Mar 11, 2026
Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study.

Anton Barchuk, Cesar Barboza, Julieta Politi

|Feb 11, 2026
Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data.

Francesco Pignatti, Tarec Christoffer El-Galaly, Martin Kaiser

|Jan 29, 2026
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Diyanath Ranasinghe, Wei-Yu Lin, Sarah E Fordham

Pageof 4

Frequent Collaborators

6 joint publications

Mika Kontro

5 joint publications

Caroline A Heckman

4 joint publications

Markus Vähä-Koskela

4 joint publications

Bjørn Tore Gjertsen